Biogen Idec
-
Biogen Idec and Elan receive notification of PDUFA date extension
Biogen Idec and Elan are working with the FDA to help facilitate a timely review of the REMS changes and the sBLA.
Biogen Idec | 20 October 2011
-
Biogen Idec, Abbott report positive results from trial of daclizumab HYP
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting mult…
Biogen Idec | 09 August 2011
-
Biogen Idec identify novel approach for treatment of multiple sclerosis
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in …
Biogen Idec | 04 July 2011
-
Biogen Idec identify novel approach for treatment of multiple sclerosis
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in …
Biogen Idec | 01 July 2011
-
Biogen Idec celebrates World MS Day
Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. The company said it continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the…
Biogen Idec | 25 May 2011
-
Biogen Idec acquires subsidiary of Neurimmune
Biogen Idec has acquired a subsidiary of Neurimmune , which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three…
Biogen Idec | 16 February 2011
